{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:00:35Z","timestamp":1758970835068},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s40265-015-0495-6","type":"journal-article","created":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T12:43:36Z","timestamp":1446813816000},"page":"2025-2034","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism"],"prefix":"10.1007","volume":"75","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohita","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,6]]},"reference":[{"issue":"Suppl 2","key":"495_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/1158583-S0-000000000-00000","volume":"70","author":"JI Abad Rico","year":"2010","unstructured":"Abad Rico JI, Llau Pitarch JV, Rocha E. Overview of venous thromboembolism. Drugs. 2010;70(Suppl 2):3\u201310.","journal-title":"Drugs."},{"issue":"Suppl 4","key":"495_CR2","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/j.amepre.2009.12.017","volume":"38","author":"MG Beckman","year":"2010","unstructured":"Beckman MG, Hooper WC, Critchley SE, et al. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38(Suppl 4):S495\u2013501.","journal-title":"Am J Prev Med"},{"issue":"10","key":"495_CR3","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.12698","volume":"12","author":"ISTH Steering Committee for World Thrombosis Day","year":"2014","unstructured":"ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014;12(10):1580\u201390.","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"495_CR4","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1002\/ajh.23128","volume":"87","author":"JA Heit","year":"2012","unstructured":"Heit JA. Predicting the risk of venous thromboembolism recurrence. Am J Hematol. 2012;87(Suppl 1):S63\u20137.","journal-title":"Am J Hematol"},{"issue":"3","key":"495_CR5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/ATVBAHA.108.182428","volume":"29","author":"T Zhu","year":"2009","unstructured":"Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol. 2009;29(3):298\u2013310.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"43","key":"495_CR6","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1093\/eurheartj\/ehu283","volume":"35","author":"SV Konstantinides","year":"2014","unstructured":"Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033\u201380.","journal-title":"Eur Heart J"},{"issue":"Suppl 2","key":"495_CR7","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","volume":"141","author":"C Kearon","year":"2012","unstructured":"Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl 2):e419S\u201394S.","journal-title":"Chest"},{"issue":"Suppl 2","key":"495_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/1158582-S0-000000000-00000","volume":"70","author":"JI Abad Rico","year":"2010","unstructured":"Abad Rico JI, Llau Pitarch JV, P\u00e1ramo Fern\u00e1ndez JA. Topical issues in venous thromboembolism. Drugs. 2010;70(Suppl 2):11\u20138.","journal-title":"Drugs."},{"key":"495_CR9","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2147\/VHRM.S50543","volume":"10","author":"A G\u00f3mez-Outes","year":"2014","unstructured":"G\u00f3mez-Outes A, Su\u00e1rez-Gea ML, Lecumberri R, et al. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. Vasc Health Risk Manag. 2014;10:627\u201339.","journal-title":"Vasc Health Risk Manag."},{"key":"495_CR10","doi-asserted-by":"crossref","unstructured":"Khoo CW, Shantsila E, Lip GYH. Vitamin K antagonists and their limitations. In: Lip GYH, Shantsila E, editors. Handbook of oral anticoagulation. Springer Healthcare Ltd.; 2013. p. 33\u201340.","DOI":"10.1007\/978-1-908517-96-8_3"},{"issue":"10","key":"495_CR11","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/j.1538-7836.2010.03989.x","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman S, Anderson DR, Bungard TJ, et al. Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost. 2010;8(10):2192\u2013200.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"495_CR12","first-page":"444","volume":"7","author":"J Cai","year":"2014","unstructured":"Cai J, Preblick R, Zhang Q, et al. Utilization of parenteral anticoagulants and warfarin: impact on the risk of venous thromboembolism recurrence in the outpatient setting. Am Health Drug Benefits. 2014;7(8):444\u201351.","journal-title":"Am Health Drug Benefits."},{"issue":"9","key":"495_CR13","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00228-013-1510-z","volume":"69","author":"S Harder","year":"2013","unstructured":"Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol. 2013;69(9):1617\u201333.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"495_CR14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12959-014-0027-8","volume":"12","author":"S McRae","year":"2014","unstructured":"McRae S. Treatment options for venous thromboembolism: lessons learnt from clinical trials. Thromb J. 2014;12(1):27.","journal-title":"Thromb J."},{"key":"495_CR15","unstructured":"US FDA. Pradaxa\u00ae (dabigatran etexilate mesylate) capsules: US prescribing information. 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022512s027lbl.pdf . Accessed 18 Sept 2015."},{"key":"495_CR16","unstructured":"European Medicines Agency. Pradaxa (dabigatran etexilate, as mesilate): summary of product characteristics. 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf . Accessed 18 Sept 2015."},{"key":"495_CR17","unstructured":"US FDA. Xarelto\u00ae (rivaroxaban) tablets: US prescribing information. 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022406s012lbl.pdf . Accessed 18 Sept 2015."},{"key":"495_CR18","unstructured":"European Medicines Agency. Xarelto (rivaroxaban): summary of product characteristics. 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf . Accessed 18 Sept 2015."},{"key":"495_CR19","unstructured":"US FDA. Eliquis\u00ae (apixaban) tablets: US prescribing information. 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/202155s011lbl.pdf . Accessed 18 Sept 2015."},{"key":"495_CR20","unstructured":"European Medicines Agency. Eliquis (apixaban): summary of product characteristics. 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf . Accessed 18 Sept 2015."},{"key":"495_CR21","unstructured":"European Medicines Agency. Lixiana (edoxaban, as tosilate): summary of product characteristics. 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002629\/WC500189045.pdf . Accessed 18 Sept 2015."},{"key":"495_CR22","unstructured":"US FDA. Savaysa\u2122 (edoxaban) tablets: US prescribing information. 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206316s002lbl.pdf . Accessed 18 Sept 2015."},{"issue":"Suppl 1","key":"495_CR23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1538-7836.2007.02473.x","volume":"5","author":"J Ansell","year":"2007","unstructured":"Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost. 2007;5(Suppl 1):60\u20134.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"495_CR24","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1160\/TH12-10-0772","volume":"109","author":"R Caterina De","year":"2013","unstructured":"De Caterina R, Husted S, Wallentin L, et al. General mechanisms of coagulation and targets of anticoagulants (section I): position paper of the ESC working group on thrombosis\u2014task force on anticoagulants in heart disease. Thromb Haemost. 2013;109(4):569\u201379.","journal-title":"Thromb Haemost"},{"key":"495_CR25","unstructured":"Daiichi-Sankyo. Daiichi Sankyo\u2019s once-daily Lixiana\u00ae (edoxaban) approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation and for the treatment and prevention of recurrent venous thromboembolism in Switzerland [media release]. 2015. http:\/\/www.daiichisankyo.com . Accessed 18 Sept 2015."},{"key":"495_CR26","unstructured":"Daiichi-Sankyo. Daiichi Sankyo receives approval for additional indications of Lixiana\u00ae (edoxaban) in Japan [media release]. 2014. http:\/\/www.daiichisankyo.com . Accessed 18 Sept 2015."},{"key":"495_CR27","unstructured":"Daiichi-Sankyo. Daiichi Sankyo launches Lixiana\u00ae (edoxaban), a direct oral factor Xa inhibitor, in Japan for the prevention of venous thromboembolism after major orthopedic surgery [media release]. 2011. http:\/\/www.daiichisankyo.com . Accessed 18 Sept 2015."},{"issue":"9","key":"495_CR28","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/j.1538-7836.2008.03064.x","volume":"6","author":"T Furugohri","year":"2008","unstructured":"Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6(9):1542\u20139.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"495_CR29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0091270009351883","volume":"50","author":"K Ogata","year":"2010","unstructured":"Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743\u201353.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"495_CR30","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1160\/TH10-11-0705","volume":"105","author":"M Wolzt","year":"2011","unstructured":"Wolzt M, Samama MM, Kapiotis S, et al. Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. Thromb Haemost. 2011;105(6):1080\u201390.","journal-title":"Thromb Haemost"},{"issue":"4","key":"495_CR31","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1160\/TH07-04-0312","volume":"98","author":"MU Zafar","year":"2007","unstructured":"Zafar MU, Vorchheimer DA, Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost. 2007;98(4):883\u20138.","journal-title":"Thromb Haemost"},{"issue":"3","key":"495_CR32","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s11239-015-1185-7","volume":"39","author":"A Cuker","year":"2015","unstructured":"Cuker A, Husseinzadeh H. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis. 2015;39(3):288\u201394.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"495_CR33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/CIRCULATIONAHA.114.013445","volume":"131","author":"H Zahir","year":"2015","unstructured":"Zahir H, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation. 2015;131(1):82\u201390.","journal-title":"Circulation"},{"issue":"8","key":"495_CR34","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1177\/0091270010381901","volume":"51","author":"J Mendell","year":"2011","unstructured":"Mendell J, Basavapathruni R, Swearingen D, et al. A thorough electrocardiogram study of edoxaban, a novel factor Xa inhibitor. J Clin Pharmacol. 2011;51(8):1241\u20136.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"495_CR35","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/FJC.0b013e3182970991","volume":"62","author":"J Mendell","year":"2013","unstructured":"Mendell J, Lee F, Chen S, et al. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. J Cardiovasc Pharmacol. 2013;62(2):212\u201321.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"15","key":"495_CR36","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"Hokusai-VTE Investigators","year":"2013","unstructured":"Investigators Hokusai-VTE, B\u00fcller HR, D\u00e9cousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406\u201315.","journal-title":"N Engl J Med"},{"issue":"4","key":"495_CR37","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1365-2125.2012.04409.x","volume":"75","author":"J Mendell","year":"2012","unstructured":"Mendell J, Noveck RJ, Shi M. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. Br J Clin Pharmacol. 2012;75(4):966\u201378.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"495_CR38","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/cpdd.53","volume":"2","author":"N Matsushima","year":"2013","unstructured":"Matsushima N, Lee F, Sato T, et al. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharmacol Drug Dev. 2013;2(4):358\u201366.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"5","key":"495_CR39","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0091270010370974","volume":"51","author":"J Mendell","year":"2011","unstructured":"Mendell J, Tachibana M, Shi M, et al. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol. 2011;51(5):687\u201394.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"495_CR40","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1124\/dmd.112.046888","volume":"40","author":"MS Bathala","year":"2012","unstructured":"Bathala MS, Masumoto H, Oguma T, et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40(12):2250\u20135.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"495_CR41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1160\/TH14-06-0547","volume":"113","author":"DA Parasrampuria","year":"2015","unstructured":"Parasrampuria DA, Marbury T, Matsushima N, et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost. 2015;113(4):719\u201327.","journal-title":"Thromb Haemost"},{"key":"495_CR42","author":"J Mendell","year":"2015","unstructured":"Mendell J, Johnson L, Chen S. An open-label, phase I study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015. doi: 10.1002\/jcph.550 .","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"495_CR43","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/dmd.113.054866","volume":"42","author":"T Mikkaichi","year":"2014","unstructured":"Mikkaichi T, Yoshigae Y, Masumoto H, et al. Edoxaban transport via P-glycoprotein is a key factor for the drug\u2019s disposition. Drug Metab Dispos. 2014;42(4):520\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"495_CR44","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40256-013-0029-0","volume":"13","author":"J Mendell","year":"2013","unstructured":"Mendell J, Zahir H, Matsushima N, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13(5):331\u201342.","journal-title":"Am J Cardiovasc Drugs."},{"issue":"7","key":"495_CR45","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/jth.12230","volume":"11","author":"G Raskob","year":"2013","unstructured":"Raskob G, B\u00fcller H, Prins M, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study\u2014methodological implications for clinical trials. J Thromb Haemost. 2013;11(7):1287\u201394.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"495_CR46","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1160\/TH10-01-0066","volume":"104","author":"JI Weitz","year":"2010","unstructured":"Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633\u201341.","journal-title":"Thromb Haemost"},{"issue":"11","key":"495_CR47","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s40265-014-0261-1","volume":"74","author":"H Bounameaux","year":"2014","unstructured":"Bounameaux H, Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs. 2014;74(11):1209\u201331.","journal-title":"Drugs."},{"issue":"9","key":"495_CR48","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s12325-010-0056-z","volume":"27","author":"SB Deitelzweig","year":"2010","unstructured":"Deitelzweig SB, Lin J, Kreilick C, et al. Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Adv Ther. 2010;27(9):623\u201333.","journal-title":"Adv Ther."},{"issue":"7","key":"495_CR49","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0149-2918(04)90187-7","volume":"26","author":"VJ Willey","year":"2004","unstructured":"Willey VJ, Bullano MF, Hauch O, et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther. 2004;26(7):1149\u201359.","journal-title":"Clin Ther"},{"issue":"9","key":"495_CR50","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/jth.13055","volume":"13","author":"M Nakamura","year":"2015","unstructured":"Nakamura M, Wang YQ, Wang C, et al. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. J Thromb Haemost. 2015;13(9):1606\u201314.","journal-title":"J Thromb Haemost"},{"issue":"22","key":"495_CR51","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104.","journal-title":"N Engl J Med"},{"issue":"5","key":"495_CR52","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ejvs.2014.05.001","volume":"48","author":"SK Kakkos","year":"2014","unstructured":"Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor\u2019s choice\u2014efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg. 2014;48(5):565\u201375.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"3","key":"495_CR53","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","volume":"12","author":"T Hulle van der","year":"2014","unstructured":"van der Hulle T, Kooiman J, den Exter PL, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):320\u20138.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"495_CR54","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ijcard.2014.08.136","volume":"177","author":"MC Vedovati","year":"2014","unstructured":"Vedovati MC, Becattini C, Germini F, et al. Efficacy and safety of direct oral anticoagulants after pulmonary embolism: a meta-analysis. Int J Cardiol. 2014;177(2):601\u20133.","journal-title":"Int J Cardiol"},{"key":"495_CR55","doi-asserted-by":"crossref","unstructured":"Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis (review). Cochrane Database Syst Rev. 2015;6:CD010956.","DOI":"10.1002\/14651858.CD010956.pub2"},{"key":"495_CR56","unstructured":"National Institute for Health and Care Excellence. Treating venous thromboembolism. 2015. http:\/\/pathways.nice.org.uk\/pathways\/venous-thromboembolism\/treating-venous-thromboembolism.pdf . Accessed 28 Sept 2015."},{"issue":"6","key":"495_CR57","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ahj.2015.03.010","volume":"169","author":"TC Sarich","year":"2015","unstructured":"Sarich TC, Seltzer JH, Berkowitz SD, et al. Novel oral anticoagulants and reversal agents: considerations for clinical development. Am Heart J. 2015;169(6):751\u20137.","journal-title":"Am Heart J"},{"key":"495_CR58","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/asheducation-2013.1.464","volume":"2013","author":"KA Bauer","year":"2013","unstructured":"Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013:464\u201370.","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"22","key":"495_CR59","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","volume":"371","author":"JE Ansell","year":"2014","unstructured":"Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141\u20132.","journal-title":"N Engl J Med"},{"issue":"2","key":"495_CR60","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/phar.1532","volume":"35","author":"Y Mo","year":"2015","unstructured":"Mo Y, Yam FK. Recent advances in the development of specific antidotes for target-specific oral anticoagulants. Pharmacotherapy. 2015;35(2):198\u2013207.","journal-title":"Pharmacotherapy."},{"issue":"21","key":"495_CR61","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1182\/blood.V124.21.4269.4269","volume":"124","author":"M Crowther","year":"2014","unstructured":"Crowther M, Levy GG, Lu G, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors [abstract no. 4269]. Blood. 2014;124(21):4269.","journal-title":"Blood"},{"issue":"3","key":"495_CR62","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11886-013-0463-2","volume":"16","author":"T Vo","year":"2014","unstructured":"Vo T, Vazquez S, Rondina MT. Current state of anticoagulants to treat deep venous thrombosis. Curr Cardiol Rep. 2014;16(3):463.","journal-title":"Curr Cardiol Rep"},{"key":"495_CR63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12959-015-0051-3","volume":"13","author":"L Bamber","year":"2015","unstructured":"Bamber L, Muston D, McLeod E, et al. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin\/vitamin K antagonist. Thromb J. 2015;13:20.","journal-title":"Thromb J."},{"issue":"6","key":"495_CR64","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.thromres.2014.03.035","volume":"133","author":"N Kang","year":"2014","unstructured":"Kang N, Sobieraj DM. Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thromb Res. 2014;133(6):1145\u201351.","journal-title":"Thromb Res"},{"issue":"2","key":"495_CR65","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11239-014-1102-5","volume":"39","author":"S Mantha","year":"2015","unstructured":"Mantha S, Ansell J. Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombolysis. 2015;39(2):155\u201365.","journal-title":"J Thromb Thrombolysis"},{"issue":"17","key":"495_CR66","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s40265-014-0301-x","volume":"74","author":"PP Dobesh","year":"2014","unstructured":"Dobesh PP, Fanikos J. New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities. Drugs. 2014;74(17):2015\u201332.","journal-title":"Drugs."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0495-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0495-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0495-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T19:40:43Z","timestamp":1692128443000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0495-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":66,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["495"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0495-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}